Comparison of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia.

Sana Urooj, Haseeb Ahmad, Maria Batool, Aymen Naeem, Ammad Saddique


Objective: To investigate the effectiveness of prophylactic intravenous magnesium sulphate in management of pre-eclemptia in terms of prevention from convulsions and developemrnt of eclempsia. Methodology: This prospective randomised trial was conducted in the department of Obtetrical and gynaecology Bahawal Vctoria Hospital, Bahawalpur. From September 2016 to September 2017. Information was entered in SPSS computer software version 23.1 and analyzed for possible results. Mean and SD was calculated and presented for quantitative data like maternal age, Gestational age, Parity and Blood pressure. Frequency (percentages) were calculated and presented for qualitative data such as gender protienurea (Yes/No), C-section, development of eclempsia and maternal death. Post stratification statistical chi square test was used to see effect modification. P value ≤ 0.05 was considered as significant. Results: In this study, a total number of 100% (n=318) patients were included, divided into two equal groups, 159 in each i.e. magnesium sulphate group and placebo group The outcomes were observed as Convulsions 2.5% (n=4) and 8.2% (n=13), maternal death1.3% (n=2) and 6.3% (n=10), adverse reaction 0.6% (n=1) and 8.2% (n=13), anti-hypertensive therapy 73.6% (n=117) and 81.8% (n=130), caesarean Section 59.7% (n=95) and 48.4% (n=77), live births 88.1% (n=140) and 97.5% (n=155) and stillbirths 21.4% (n=34) and 12.6% (n=20) for magnesium sulphate group and placebo group respectively. In Mgso4 group 95% patients have good efficacy and placebo group have 84.3% good efficacy. Conclusion: Relative small incidence of convulsions (2.5%) was found in Mgso4 group, so administration of Magnesium sulphate should considered in management of pre-eclempsia.

Full Text: PDF
Download the IISTE publication guideline!

To list your conference here. Please contact the administrator of this platform.

Paper submission email:

ISSN 2422-8427

Please add our address "" into your email contact list.

This journal follows ISO 9001 management standard and licensed under a Creative Commons Attribution 3.0 License.

Copyright ©